What is the recommended dosing regimen for nifedipine in adults, including immediate‑release and extended‑release formulations?

Nifedipine Dosing Recommendations

For adults with hypertension or angina, nifedipine extended-release formulations should be initiated at 30 mg once daily and titrated over 7-14 days to a usual maintenance dose of 30-60 mg once daily, with a maximum of 90 mg daily; immediate-release nifedipine (30-90 mg daily in divided doses) should be avoided except when combined with beta-blocker therapy, particularly in acute coronary syndromes. 1, 2, 3

Extended-Release Formulations (Preferred)

Standard Dosing

• Starting dose: 30 mg once daily on an empty stomach 3
• Titration: Increase over 7-14 days based on therapeutic response and tolerability 3
• Usual maintenance: 30-60 mg once daily 1, 2, 3
• Maximum dose: 90 mg daily (doses above 90 mg are not recommended) 3

Administration Guidelines

• Tablets must be swallowed whole—never crushed, chewed, or divided 3
• Take on an empty stomach for optimal absorption 3
• Avoid grapefruit juice: Can increase nifedipine levels up to 2-fold through CYP3A4 inhibition 3

Dose Equivalency Considerations

Two 30 mg tablets can substitute for one 60 mg tablet, but three 30 mg tablets produce 29% higher peak concentrations than a single 90 mg tablet and should not be considered interchangeable 3

Immediate-Release Formulations

Dosing Range

• Standard dose: 30-90 mg daily orally (divided doses) 1, 2, 1
• Duration of action: Short 1, 2

Critical Safety Restrictions

Immediate-release nifedipine carries significant safety concerns and should be avoided in specific clinical scenarios:

• Class III Harm recommendation: Do not use in NSTE-ACS (non-ST-elevation acute coronary syndromes) without concurrent beta-blocker therapy 4, 5
• Rapid-release formulations must be avoided without concomitant beta blockade due to increased risk of adverse cardiovascular events including myocardial infarction, reflex tachycardia, and worsening ischemia 1, 6
• Associated with dose-related mortality increase in coronary artery disease when used alone 5

Special Populations

Elderly Patients (>60 years)

• Start at lower end of dosing range
• Elderly patients show 36% higher peak concentrations and 70% greater average plasma levels compared to younger patients 3
• Elimination half-life is prolonged (6.7 hours vs 3.8 hours in young subjects) 3

Hepatic Impairment

• Use caution and consider dose reduction
• Longer elimination half-life and higher bioavailability in liver cirrhosis 3
• Protein binding significantly reduced (normally 92-98%) 3

Renal Impairment

• Exercise caution as absorption may be modified by renal disease 3
• Protein binding may be greatly reduced 3

Pregnancy (Hypertensive Emergencies)

• Immediate-release: 10-20 mg orally, repeat in 20 minutes if needed
• Then 10-20 mg every 2-6 hours
• Maximum: 180 mg daily 7
• Onset of action: 5-10 minutes 7

Clinical Context by Indication

Hypertension

Extended-release formulations provide smooth 24-hour blood pressure control with once-daily dosing. The 30-60 mg daily range achieves adequate control in most patients 1, 2, 3. Studies demonstrate dose-proportional efficacy, with 20 mg showing significant antihypertensive effect compared to placebo 8.

Angina/Acute Coronary Syndromes

• Preferred: Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) over nifedipine for ACS 1, 4, 5
• If nifedipine is used: Only extended-release formulations with concurrent beta-blocker therapy 1
• Avoid in patients with severe LV dysfunction, pulmonary edema, or increased shock risk 1

Common Pitfalls to Avoid

1. Never use immediate-release nifedipine without beta-blocker coverage in patients with coronary disease—this carries a Class III Harm designation 4, 5

2. Do not crush or divide extended-release tablets—this destroys the controlled-release mechanism and creates immediate-release kinetics 3

3. Avoid co-administration with grapefruit juice—doubles drug exposure through CYP3A4 inhibition 3

4. Do not abruptly discontinue—taper gradually under physician supervision 3

5. Watch for excessive hypotension when combining with other antihypertensives or in elderly patients—27% of critically ill patients experienced clinically significant hypotension in one study 9

Discontinuation

When stopping nifedipine extended-release, decrease dosage gradually with close physician supervision rather than abrupt cessation 3.